New answer by Medical Oncologist at University of North Carolina at Chapel Hill (April 2, 2025)
My recommendation for therapy would be dependent on the individual patient. In the CheckMate 274 trial, patients with ypT2-ypT4a disease or ypN+ muscle invasive urothelial car...